Fasching PA, et al. - Researchers determined the impacts of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with triple-negative breast cancer (TNBC)[from the GeparQuinto study] treated with anthracycline and taxane–containing chemotherapy, with or without bevacizumab. They found that in patients with TNBC with BRCA1/2 mutations, the addition of bevacizumab could increase the pCR after standard neoadjuvant chemotherapy. They also observed that pCR was a weaker predictor of DFS for BRCA1/2 mutation carriers vs for patients without mutations in patients treated with anthracycline and taxane–based chemotherapy (with or without bevacizumab).